

CITATION REPORT

List of articles citing

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment

DOI: 10.1128/aac.00132-22

Antimicrobial Agents and Chemotherapy, , , .

Source: <https://exaly.com/paper-pdf/146211644/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery. 12,		0
3	Upcycling known molecules and targets for drug-resistant TB. 12,		0
2	The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis. 2022 , 82, 1695-1715		1
1	Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286.		0